{"filing":{"accession_number":"0001193125-26-326851","cik":"0001885827","ticker":"VRAX","company_name":"Virax Biolabs Group Ltd","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"6-k_special_meeting_auth.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885827/000119312526326851/6-k_special_meeting_auth.htm"},"events":[{"id":22790,"run_id":20625,"accession_number":"0001193125-26-326851","anchor_item_number":"EX-99.1","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Virax Biolabs Group Ltd is soliciting shareholder approval for three material proposals at an Extraordinary General Meeting scheduled for August 14, 2026: (1) a Share Capital Increase from 2 million to 500 million authorized ordinary shares (a 250x expansion providing significant transactional and financing flexibility), (2) adoption of amended and restated articles of association, and (3) an adjournment proposal.","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":[{"id":22842,"accession_number":"0001193125-26-326851","item_number":"EX-99.1","item_title":"vrax-ex99_1.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a Notice of Extraordinary General Meeting and Proxy Statement soliciting shareholder approval for three proposals: (1) a Share Capital Increase from 2 million to 500 million authorized ordinary shares, (2) adoption of amended and restated articles of association, and (3) an adjournment proposal. While technically this is a notice *calling* the meeting rather than reporting *results* of a vote, the substance is a shareholder vote on material governance and capital structure matters. The Share Capital Increase is material as it expands authorized shares by 250x, providing significant transactional and financing flexibility. The charter amendment is also material. This is classified as shareholder_vote_results because the exhibit's primary purpose is to solicit and facilitate shareholder voting on material proposals, though the actual vote results are not yet disclosed (the meeting is scheduled for August 14, 2026).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:19.880628+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":22791,"run_id":20625,"accession_number":"0001193125-26-326851","anchor_item_number":"EX-99.3","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"summary":"The Fifth Amended and Restated Memorandum and Articles of Association of Virax Biolabs Group Limited were adopted by special resolution, representing routine corporate governance documentation updates.","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":[{"id":22843,"accession_number":"0001193125-26-326851","item_number":"EX-99.3","item_title":"vrax-ex99_3.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit is the Fifth Amended and Restated Memorandum and Articles of Association of Virax Biolabs Group Limited — foundational corporate governance documents adopted by special resolution. While governance-related, the filing of amended articles and memorandum is routine administrative disclosure that does not affect a reasonable investor's assessment of the company's financial condition, operations, or material risks. Such filings are standard corporate housekeeping and do not constitute a discrete material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:19.880628+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22842,"accession_number":"0001193125-26-326851","item_number":"EX-99.1","item_title":"vrax-ex99_1.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a Notice of Extraordinary General Meeting and Proxy Statement soliciting shareholder approval for three proposals: (1) a Share Capital Increase from 2 million to 500 million authorized ordinary shares, (2) adoption of amended and restated articles of association, and (3) an adjournment proposal. While technically this is a notice *calling* the meeting rather than reporting *results* of a vote, the substance is a shareholder vote on material governance and capital structure matters. The Share Capital Increase is material as it expands authorized shares by 250x, providing significant transactional and financing flexibility. The charter amendment is also material. This is classified as shareholder_vote_results because the exhibit's primary purpose is to solicit and facilitate shareholder voting on material proposals, though the actual vote results are not yet disclosed (the meeting is scheduled for August 14, 2026).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:19.880628+00:00","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-07-31"},{"id":22843,"accession_number":"0001193125-26-326851","item_number":"EX-99.3","item_title":"vrax-ex99_3.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit is the Fifth Amended and Restated Memorandum and Articles of Association of Virax Biolabs Group Limited — foundational corporate governance documents adopted by special resolution. While governance-related, the filing of amended articles and memorandum is routine administrative disclosure that does not affect a reasonable investor's assessment of the company's financial condition, operations, or material risks. Such filings are standard corporate housekeeping and do not constitute a discrete material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:26:19.880628+00:00","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-07-31"}]}